HUNTSVILLE, AL, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made grants of options to purchase an aggregate of 60,500 shares of Serina's common stock to three new non-executive employees on November 6, 2024 (each, an "Option Grant”). Each Option Grant has an exercise price equal to the closing price of Serina's common stock on November 6, 2024. The Option Grants were offered as material inducement to the employees' employment. The Option Grants were approved by the Compensation Committee of Serina's Board of Directors on November 6, 2024 pursuant to Serina's 2024 Inducement Equity Plan to align their interests with Serina's stockholders and to promote the success of Serina's business. The Option Grants were made in reliance on the employment inducement exemption under the NYSE American's Company Guide Section 711(a) which requires public disclosure of inducement awards. Serina is issuing this press release pursuant to Section 711(a) of NYSE American's Company Guide. The Option Grants shall vest and become exercisable with respect to one-third of the aggregate number of shares subject to each Option Grant on the first anniversary of the grant date, and the remaining two-thirds of the aggregate number of shares subject to each Option Grant shall vest in a series of 24 substantially equal monthly installments thereafter, such that the Option Grant will be vested as of the third anniversary of the grant date, subject to continued employment with Serina.

About Serina Therapeutics

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina's POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.

For more information, please visit https://serinatherapeutics.com.

Cautionary Statement Regarding Forward-Looking Statement

This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management's current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina's POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in Serina's Annual Report on Form 10-K for the year ended December 31, 2023, Serina's Current Report on Form 8-K that was filed with the SEC on April 1, 2024, and Serina's other periodic reports and documents filed from time to time with the SEC.

The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

For inquiries, please contact:

Investor.relations@serinatherapeutics.com

(256) 327-9630